Peptidoglycan and lipoteichoic acid modify monocyte phenotype in human whole blood.
We examined the influence of the gram-positive cell wall products peptidoglycan (PepG) and lipoteichoic acid (LTA), compared to lipopolysaccharide (LPS), on the monocyte expression of receptors involved in antigen presentation (HLA-DR, B7.1, and B7.2), cell adhesion (intercellular adhesion molecule-1 [ICAM-1] and lymphocyte function associated antigen-3 [LFA-3]), phagocytosis (Fc gamma RI), and cell activation (CD14). We also evaluated possible influences of the immunosuppressive drugs cyclosporine A, tacrolimus, and sirolimus on the expression of these receptors. Pretreatment of whole blood for 4 h with the immunosuppressive drugs did not influence the expression of the surface receptors in normal or stimulated blood. Stimulation with both PepG and LTA caused significant up-regulation of the surface expression of ICAM-1 and HLA-DR on whole blood monocytes, similar to that obtained with LPS, whereas B7.1, B7.2, LFA-3, and Fc gamma RI were not modulated. PepG and LTA also caused increased expression of CD14, whereas LPS down-regulated this molecule. In contrast, we did not detect any significant influence of any of the bacterial products on the plasma concentration of soluble CD14. We hypothesized that the increased expression of surface CD14 in blood stimulated with PepG would prime for cellular activation by LPS. Indeed, we show that PepG and the partial PepG structure muramyl dipeptide acted in synergy with LPS to cause the release of tumor necrosis factor-alpha. The results suggest that PepG and LPS provoke partly different responses on monocyte phenotype and that CD14 may play different roles in the innate response to gram-positive and gram-negative bacteria.
Jørgensen
P F
PF
Institute for Surgical Research, University of Oslo, The National Hospital, N-0027 Oslo, Norway. p.f.jorgensen@klinmed.uio.no
Wang
J E
JE
Almlöf
M
M
Thiemermann
C
C
Foster
S J
SJ
Solberg
R
R
Aasen
A O
AO
D017951:Antigen Presentation / Q000187:drug effects; D018968:CD58 Antigens / Q000096:biosynthesis; D002448:Cell Adhesion / Q000187:drug effects; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects* / Q000502:physiology; D010457:Peptidoglycan / Q000494:pharmacology*; D010587:Phagocytosis / Q000187:drug effects; D017452:Receptors, IgG / Q000096:biosynthesis; D013682:Teichoic Acids / Q000494:pharmacology*
D018968:CD58 Antigens; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D010457:Peptidoglycan; D017452:Receptors, IgG; D013682:Teichoic Acids; D018799:Intercellular Adhesion Molecule-1; C009900:lipoteichoic acid